Canonical Question
Phaemacopeia – Haematology
Master answer
Haemostasis: the physiological processes which arrest bleeding
Drugs which reduce blood flow:
- Adrenaline: causes local vasoconstriction
- Wound glue: physical barrier to reduce bleeding
Drugs which increase the available coagulation factors:
- Desmopressin: increases plasma levels of FVIII and von Willebrand Factor, which promote formation of the platelet plug and participate in the coagulation cascade
- Vitamin K: required for the gamma-carboxylation of coagulation factors II, VII, IX and X to activate them in the clotting cascade. Also activates proteins C and S. Vitamin K may be given to reverse supratherapeutic INR associated with warfarin use; may also be given in liver disease or other situations when the INR is elevated and potential bleeding is a concern.
- Prothrombinex: powder for injection containing 500IU each of FII, IX and X, low levels of FV and VII, 25mg of antithrombin which participate in the coagulation cascade as normal
- Biostate: Human derived FVIII/VWF complex which can participate in the coagulation cascade
- Other factor concentrates
Drugs which reduce clot breakdown:
- Tranexamic acid: acts by inhibiting the binding of plasminogen and plasmin to fibrin, to inhibit fibrinolysis of a formed clot
- Aprotinin: a naturally occurring proteolytic enzyme inhibitor acting on trypsin, plasmin and tissue kallikrein. It inhibits the fibrinolytic activity of the streptokinase-plasminogen complex and decreases activation of the clotting cascade.
- Aminocaproic acid: Binds competitively to plasminogen, blocks the binding of plasminogen to fibrin and subsequent conversion to plasmin, resulting in inhibition of fibrinolysis
- Oestrogen: inhibits Protein C (naturally occurring regulator of haemostasis)
Drugs which reverse anticoagulants:
- Vitamin K: as above
- Protamine sulfate: binds to heparin in circulation to produce a stable inactive complex for removal by reticuloendothelial system. Useful in cases of bleeding associated with heparin use.
- Idarucizumab: specific reversal agent for dabigatran
- Andexanet Alfa: Recombinant protein that inactivates direct factor Xa inhibitors like Rivaroxaban as well as antithrombin activated by LMWH or Fondaparinux
JC 2019
Exam appearances
| Exam | Exact wording | Relationship | Success |
|---|---|---|---|
| 2009A Q05 | Outline the mechanism of action of drugs used to promote haemostasis. | historical_member | — |